Daihan Pharmaceutical Co.Ltd (023910) - Net Assets
Based on the latest financial reports, Daihan Pharmaceutical Co.Ltd (023910) has net assets worth ₩293.27 Billion KRW (≈ $198.74 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩344.02 Billion ≈ $233.14 Million USD) and total liabilities (₩50.75 Billion ≈ $34.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Daihan Pharmaceutical Co.Ltd to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩293.27 Billion |
| % of Total Assets | 85.25% |
| Annual Growth Rate | 15.72% |
| 5-Year Change | 51.71% |
| 10-Year Change | 259.18% |
| Growth Volatility | 5.47 |
Daihan Pharmaceutical Co.Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Daihan Pharmaceutical Co.Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Daihan Pharmaceutical Co.Ltd market cap and net worth.
Annual Net Assets for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual net assets of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. Also explore how fast is Daihan Pharmaceutical Co.Ltd growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩275.99 Billion ≈ $187.04 Million |
+11.30% |
| 2023-12-31 | ₩247.97 Billion ≈ $168.05 Million |
+10.02% |
| 2022-12-31 | ₩225.40 Billion ≈ $152.75 Million |
+11.14% |
| 2021-12-31 | ₩202.81 Billion ≈ $137.44 Million |
+11.48% |
| 2020-12-31 | ₩181.92 Billion ≈ $123.29 Million |
+9.08% |
| 2019-12-31 | ₩166.78 Billion ≈ $113.02 Million |
+18.82% |
| 2018-12-31 | ₩140.36 Billion ≈ $95.12 Million |
+21.13% |
| 2017-12-31 | ₩115.88 Billion ≈ $78.53 Million |
+24.68% |
| 2016-12-31 | ₩92.94 Billion ≈ $62.99 Million |
+20.96% |
| 2015-12-31 | ₩76.84 Billion ≈ $52.07 Million |
+19.88% |
| 2014-12-31 | ₩64.10 Billion ≈ $43.44 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Daihan Pharmaceutical Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 438.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩276.24 Billion | 100.09% |
| Common Stock | ₩3.00 Billion | 1.09% |
| Total Equity | ₩275.99 Billion | 100.00% |
Daihan Pharmaceutical Co.Ltd Competitors by Market Cap
The table below lists competitors of Daihan Pharmaceutical Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maxigen Biotech Inc
TW:1783
|
$108.21 Million |
|
Devyser Diagnostics AB
ST:DVYSR
|
$108.22 Million |
|
Canadian Life Companies Split Corp
TO:LFE
|
$108.25 Million |
|
Kino Indonesia Tbk PT
JK:KINO
|
$108.26 Million |
|
RMK Energy PT Tbk
JK:RMKE
|
$108.18 Million |
|
Tera Autotech
TWO:6234
|
$108.17 Million |
|
Meiloon Industrial Co Ltd
TW:2477
|
$108.16 Million |
|
Schloss Wachenheim AG
F:SWA
|
$108.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daihan Pharmaceutical Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 247,974,088,070 to 275,993,788,750, a change of 28,019,700,680 (11.3%).
- Net income of 33,759,099,690 contributed positively to equity growth.
- Dividend payments of 4,329,000,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩33.76 Billion | +12.23% |
| Dividends Paid | ₩4.33 Billion | -1.57% |
| Other Changes | ₩-1.41 Billion | -0.51% |
| Total Change | ₩- | 11.30% |
Book Value vs Market Value Analysis
This analysis compares Daihan Pharmaceutical Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.58x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.75x to 0.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩15490.58 | ₩27150.00 | x |
| 2017-12-31 | ₩19313.43 | ₩27150.00 | x |
| 2018-12-31 | ₩23393.61 | ₩27150.00 | x |
| 2019-12-31 | ₩27795.88 | ₩27150.00 | x |
| 2020-12-31 | ₩30320.57 | ₩27150.00 | x |
| 2021-12-31 | ₩33801.34 | ₩27150.00 | x |
| 2022-12-31 | ₩37566.35 | ₩27150.00 | x |
| 2023-12-31 | ₩42172.46 | ₩27150.00 | x |
| 2024-12-31 | ₩46937.72 | ₩27150.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daihan Pharmaceutical Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.23%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.53%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.18x
- Recent ROE (12.23%) is below the historical average (15.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 16.26% | 9.33% | 0.85x | 2.05x | ₩4.01 Billion |
| 2015 | 17.93% | 11.09% | 0.90x | 1.81x | ₩6.09 Billion |
| 2016 | 19.00% | 12.66% | 0.87x | 1.72x | ₩8.36 Billion |
| 2017 | 21.43% | 17.19% | 0.78x | 1.59x | ₩13.24 Billion |
| 2018 | 20.32% | 17.97% | 0.68x | 1.67x | ₩14.48 Billion |
| 2019 | 16.89% | 16.69% | 0.68x | 1.48x | ₩11.49 Billion |
| 2020 | 9.55% | 10.47% | 0.66x | 1.39x | ₩-811.55 Million |
| 2021 | 11.18% | 13.22% | 0.63x | 1.34x | ₩2.39 Billion |
| 2022 | 11.07% | 13.55% | 0.67x | 1.23x | ₩2.42 Billion |
| 2023 | 11.46% | 14.51% | 0.67x | 1.19x | ₩3.63 Billion |
| 2024 | 12.23% | 16.53% | 0.63x | 1.18x | ₩6.16 Billion |
Industry Comparison
This section compares Daihan Pharmaceutical Co.Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $325,084,657,501
- Average return on equity (ROE) among peers: -2.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daihan Pharmaceutical Co.Ltd (023910) | ₩293.27 Billion | 16.26% | 0.17x | $108.19 Million |
| Dongwha Pharm.Co.Ltd (000020) | $227.23 Billion | 0.45% | 0.39x | $97.86 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.06 Billion |
| Yuhan Corp Preferred (000105) | $1.36 Trillion | 9.24% | 0.38x | $45.29 Million |
| Yuyu Pharma (000220) | $73.73 Billion | -0.34% | 0.41x | $42.11 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $14.43 Million |
| Yuyu Pharma Inc (000227) | $135.06 Billion | 6.46% | 0.54x | $30.10 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $49.27 Million |
| Samil Pharm (000520) | $125.82 Billion | -0.02% | 1.84x | $89.63 Million |
| Donga Socio Holdings (000640) | $514.60 Billion | 3.03% | 0.92x | $404.02 Million |
| Jw Pharmac (001060) | $200.74 Billion | 1.12% | 1.94x | $420.24 Million |
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.